Asset Details
Do you wish to reserve the book?
Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia
Do you wish to request the book?
Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia
2022
Overview
The incidence of obesity is rising with greater than 40% of the world’s population expected to be overweight or suffering from obesity by 2030. This is alarming because obesity increases mortality rates in patients with various cancer subtypes including leukemia. The survival differences between lean patients and patients with obesity are largely attributed to altered drug pharmacokinetics in patients receiving chemotherapy; whereas, the direct impact of an adipocyte-enriched microenvironment on cancer cells is rarely considered. Here we show that the adipocyte secretome upregulates the surface expression of Galectin-9 (GAL-9) on human B-acute lymphoblastic leukemia cells (B-ALL) which promotes chemoresistance. Antibody-mediated targeting of GAL-9 on B-ALL cells induces DNA damage, alters cell cycle progression, and promotes apoptosis in vitro and significantly extends the survival of obese but not lean mice with aggressive B-ALL. Our studies reveal that adipocyte-mediated upregulation of GAL-9 on B-ALL cells can be targeted with antibody-based therapies to overcome obesity-induced chemoresistance.
Obesity has been reported to promote tumourigenesis and chemoresistance but the underlying mechanisms are not completely understood. Here, the authors show that adipocytes induce Galectin-9 (GAL-9) expression in B-acute lymphoblastic leukaemia (B-ALL) cells which leads to chemoresistance and antibody-mediated blockade of GAL-9 increases survival in preclinical B-ALL murine models.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/2
/ 13/21
/ 13/31
/ 13/95
/ 14
/ 14/19
/ 38
/ 38/39
/ 38/91
/ 64
/ 64/60
/ Acute lymphoblastic leukemia
/ Animals
/ Burkitt Lymphoma - drug therapy
/ Burkitt Lymphoma - metabolism
/ Burkitt Lymphoma - pathology
/ Cancer
/ Humanities and Social Sciences
/ Humans
/ Leukemia
/ Mice
/ Obesity
/ Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
/ Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism
/ Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
/ Science
/ Survival
